2020
DOI: 10.1101/2020.12.22.424018
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

In vivogenetic screen identifies a SLC5A3-dependent myo-inositol auxotrophy in acute myeloid leukemia

Abstract: An enhanced requirement for extracellular nutrients is a hallmark property of cancer cells. Here, we optimized an in vivo genetic screening strategy for evaluating dependencies in acute myeloid leukemia (AML), which led to the identification of the myo-inositol transporter SLC5A3 as a unique vulnerability in this disease. In accord with this transport function, we demonstrate that the SLC5A3 dependency reflects a myo-inositol auxotrophy in AML. Importantly, the commonality among SLC5A3-dependent AML lines is t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
5
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
3
2

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(5 citation statements)
references
References 90 publications
0
5
0
Order By: Relevance
“…Lee et al developed a new nanopore sequencing-based method to simultaneously detect CpG methylation and chromatin accessibility [86]. Also, several preprint papers report the use of nanopore sequencing to enhance the understanding of epigenetic heterogeneity and the underlying molecular mechanisms [87][88][89].…”
Section: Discussionmentioning
confidence: 99%
“…Lee et al developed a new nanopore sequencing-based method to simultaneously detect CpG methylation and chromatin accessibility [86]. Also, several preprint papers report the use of nanopore sequencing to enhance the understanding of epigenetic heterogeneity and the underlying molecular mechanisms [87][88][89].…”
Section: Discussionmentioning
confidence: 99%
“…In addition, patients with AML and loss of inositol-3-phosphate synthase 1 (ISYNA1) have shown a dependency on extracellular myo-Inositol (Wei et al ., 2020). In this study, the inhibition of the myo-Inositol transporter SLC5A3 was presented as a good proxy for myo-Inositol depletion.…”
Section: Resultsmentioning
confidence: 99%
“…The dependence on L-asparagine in ALL is one paradigmatic example that is used clinically in patients with acute lymphoblastic leukemia. Other ongoing works include cholesterol depletion in lymphoma (Garcia-Bermudez et al ., 2019) and myo-inositol depletion in AML (Wei et al ., 2020), which illustrate that this therapeutic strategy could be exploited in wider settings. All together emphasizes the importance of systematically considering the nutrient environment to target cancer metabolism via synthetic lethality approaches (Muir and Vander Heiden, 2018).…”
Section: Discussionmentioning
confidence: 99%
“…In addition, patients with AML and loss of inositol-3-phosphate synthase 1 (ISYNA1) have shown a dependency on extracellular myo-Inositol [30]. In this study, the inhibition of the myo-Inositol transporter SLC5A3 was presented as a good proxy for myo-Inositol depletion.…”
Section: Extracellular Nutrient Dependences Of Tumor Cellsmentioning
confidence: 88%
“…The dependence on L-asparagine is one paradigmatic example that is used clinically in patients with acute lymphoblastic leukemia. Other ongoing works include cholesterol depletion in lymphoma [29] and myo-Inositol depletion in AML [30], which illustrate that this therapeutic strategy could be exploited in wider settings. All these results together emphasize the importance of systematically considering the nutrient environment to target cancer metabolism via synthetic lethality approaches [32].…”
Section: Discussionmentioning
confidence: 99%